معرفی
Rong Xu is a Research Fellow at Monash University, affiliated with the Australian Centre for Blood Diseases and the Victorian Heart Institute (VHI), working in the laboratory of Prof Christoph Hagemeyer. She received her PhD in Biochemistry and Exosomes Research in 2017 from La Trobe University under the supervision of Prof Richard Simpson and A/Prof David Greening, and previously held a Research Fellow position there until mid-2020.
- PhD in Biochemistry and Exosomes Research, La Trobe University (2017)
Her research focuses on developing smart therapeutic systems, particularly injury-responsive exosomes for cardiovascular disease prevention (e.g., acute myocardial infarction, stroke) and glucose-responsive insulin nanoparticles for diabetes therapy. She also employs advanced imaging techniques—such as ultrasound, photoacoustic imaging (Vevo F2), PET, MRI, MPI, and CT—to study disease mechanisms and therapy efficacy. Her work intersects with multiple areas of nanomedicine, molecular imaging, and targeted delivery systems. She utilizes phage libraries to discover novel targeting antibodies for disease-specific applications.
Recent publications (2024) highlight her contributions to extracellular vesicle proteomics and transcriptomics, consensus guidelines (MISEV2023), molecular imaging of cardiac fibrosis, and insulin analog synthesis. These works reflect a strong trend in precision biomedicine, with emphasis on extracellular vesicle biology, diagnostic imaging, and therapeutic innovation for chronic diseases.
Scientific awards and recognitions include:
- Millennium Science Fellowship Program (2021)
- Monash Future Leader Postdoctoral Fellowship (2022)
- JDRF Early and Mid-Career Basic Researcher Fellowship (2024–2026)
- CASS Foundation Medicine/Science Grant (2023)
- Bethlehem Griffiths Research Foundation Grant (2023)
Rong Xu has been actively involved in research leadership and academic service. She is the Primary Chief Investigator on a project funded by the CASS Foundation to develop targeted nano-carriers for stroke treatment. She has also served as an Associate Editor for Frontiers in Oncology, Guest Editor for Pharmaceutics and Frontiers in Cellular Neuroscience, and Session Chair at academic conferences. Her editorial and organizational roles demonstrate substantial contributions to the scientific community. She leads multiple grant-funded projects and has no indication of advising formal PhD or Master’s students at this stage.
She is a key member of research teams at both Monash University and previously at La Trobe University, collaborating with leading scientists such as Prof Christoph Hagemeyer, Prof Richard Simpson, and A/Prof David Greening. Her current work is centered at the Victorian Heart Institute, where she contributes to cutting-edge cardiovascular and diabetes research.
